Clinicians in Conversation: CLARITY IBD - Pragmatic pointers from a trial delivered in a pandemic

National Institute for Health and Care Research

Professor Tariq Iqbal talks to Dr Tariq Ahmad about CLARITY IBD, the most important gastroenterology study undertaken during the recent COVID pandemic.
In this episode they discuss how this pragmatic trial adopted an agile approach to rapidly answer a key question: Do common immunosuppressants used to treat Inflammatory Bowel Disease (IBD) reduce the effectiveness of COVID19 vaccines?
They also explain how this study, which involves almost 7,000 participants from 92 UK hospitals, was set up and recruited to at an unprecedented speed.
The CLARITY trial is looking at the impact of two biologic medicines (infliximab and vedolizumab) on COVID-19 infection, vaccination and immune response in people with IBD conditions such as Crohn’s or Colitis. Learn more about the CLARITY IBD study.
The views and opinions expressed in this podcast are those of the host and guests and do not necessarily reflect those of the NIHR or the Department of Health and Social Care.
Transcript: https://docs.google.com/document/d/1GvrOU2Y0DnWbbjn--6_UIpCupqrhJKhk/edit?usp=sharing&ouid=114082658712200237854&rtpof=true&sd=true